Literature DB >> 11254673

LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor.

E Koustova1, Y Sei, L Fossom, M L Wei, P N Usherwood, N B Keele, M A Rogawski, A S Basile.   

Abstract

Autoantibodies to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors may contribute to chronic hyperexcitability syndromes and neurodegeneration, but their origin is unclear. We examined LP-BM5 murine leukemia virus-infected mice, which manifest excitotoxic brain lesions and hypergammaglobulinemia, for the presence of AMPA-receptor Ab's. Endogenous IgG accumulated upon neurons in the neocortex and caudate/putamen of infected mice and interacted with native and recombinant AMPA-receptor subunits with the following relative abundance: GluR3 > or = GluR1 > GluR2 = GluR4, as determined by immunoprecipitation. In a radioligand assay, IgG preparations from infected mice specifically inhibited [(3)H]AMPA binding to receptors in brain homogenates, an activity that was lost after preadsorbing the IgG preparation to immobilized LP-BM5 virus. These IgGs also evoked currents when applied to hippocampal pyramidal neurons or to damaged cerebellar granule neurons. These currents could be blocked using any of several AMPA receptor antagonists. Thus, anti-AMPA-receptor Ab's can be produced as the result of a virus infection, in part through molecular mimicry. These Ab's may alter neuronal signaling and contribute to the neurodegeneration observed in these mice, actions that may be curtailed by the use of AMPA-receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254673      PMCID: PMC208947          DOI: 10.1172/JCI11500

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins.

Authors:  Y Stern-Bach; B Bettler; M Hartley; P O Sheppard; P J O'Hara; S F Heinemann
Journal:  Neuron       Date:  1994-12       Impact factor: 17.173

2.  Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A.

Authors:  K M Partin; D K Patneau; C A Winters; M L Mayer; A Buonanno
Journal:  Neuron       Date:  1993-12       Impact factor: 17.173

3.  GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.

Authors:  S D Donevan; M A Rogawski
Journal:  Neuron       Date:  1993-01       Impact factor: 17.173

Review 4.  Cloned glutamate receptors.

Authors:  M Hollmann; S Heinemann
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

5.  Defective T cell receptor-mediated signaling and differential induction of T cell functions by murine AIDS virus superantigen.

Authors:  O Kanagawa; M E Wiebenga; B A Vaupel
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

Review 6.  Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome.

Authors:  S A Lipton; H E Gendelman
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

7.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

Review 8.  Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Martin; H F McFarland
Journal:  Crit Rev Clin Lab Sci       Date:  1995       Impact factor: 6.250

9.  Properties of AMPA receptors expressed in rat cerebellar granule cell cultures: Ca2+ influx studies.

Authors:  N Hack; R Balázs
Journal:  J Neurochem       Date:  1995-09       Impact factor: 5.372

10.  Evaluation of autoantibodies to brain proteins in patients with AIDS dementia complex.

Authors:  J R Trujillo; B Navia; M F McLane; J L Worth; T H Lee; M Essex
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.